|
| Scientific Program |
| |
|
| Scientific Program | Search Abstract |
| |
|
|
| Session |
| |
| Chronic myeloid leukemia - Clinical I |
| Date: |
Saturday, 06 June 2009
|
| Time: | 08:00-09:15 |
| Room: | Hall 3 |
| |
| 08:00-08:15 |
|
SUBCUTANEOUS OMACETAXINE MEPESUCCINATE IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS (PTS) WITH THE T315I MUTATION – DATA FROM AN ONGOING PHASE 2/3 TRIAL
| 0476 |
| Cortes, Jorge,
Khoury, Hanna,
Nicolini, Franck,
Corm, Selim,
Schenk, T.,
Hochhaus, Andreas,
Jones, Dan,
Kantarjian, Hagop,
Craig, Adam,
Benichou, Annie-Claude,
Humphriss, Eric,
Michallet, Mauricette
(Houston, United States of America) |
| |
| 08:15-08:30 |
|
MULTICENTER OPEN LABEL STUDY OF SUBCUTANEOUS (SC) OMACETAXINE MEPESUCCINATE IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS THAT ARE RESISTANT OR INTOLERANT TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKIS)
| 0477 |
| Wetzler, Meier,
Parikh, PM,
Raghunadharao, D,
Jones, Dan,
Leitner, A,
Hochhaus, Andreas,
Benichou, Annie-Claude,
Craig, Adam,
Humphriss, Eric,
Kantarjian, Hagop,
Cortes, Jorge
(Buffalo, United States of America) |
| |
| 08:30-08:45 |
|
RANDOMIZED CLINICAL TRIAL FOR THE OPTIMIZATION OF IMATINIB THERAPY BY COMBINATION, DOSE ESCALATION AND TRANSPLANTATION.
DESIGNED FIRST INTERIM ANALYSIS OF THE GERMAN CML STUDY IV
| 0478 |
| Hehlmann, Rüdiger,
Saußele, S.,
Lauseker, M.,
Leitner, A.,
Pletsch, N.,
Haferlach, C.,
Schlegelberger, B.,
Müller, M. C.,
Schenk, T.,
Pfirrmann, M.,
Ehninger, G.,
Fischer, T.,
Hasford, J.,
Hochhaus, A.,
Hossfeld, D. K.,
Kolb, H. J.,
Krause, S. W.,
Nerl, C.,
Pralle, H.,
Gratwohl, A.,
Tobler, A.,
Heimpel, H.,
Balleisen, L.,
Einsele, H.,
Ho, A. D.,
Falge, C.,
Hänel, M.,
Pfreundschuh, M.,
Kanz, L.,
Döhner, H.,
Köhne, C.,
Kremers, S.,
Spiekermann, K.,
Berdel, W.,
Waller, C. F.,
Bentz, M.,
And, The German CML Study Group
(Mannheim, Germany) |
| |
| 08:45-09:00 |
|
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN THE ERA OF TARGETED THERAPY: COMPARABLE SURVIVAL RATES FOLLOWING ALLOGENEIC HSCT AFTER IMATINIB AND IMATINIB THERAPY IN FIRST CHRONIC PHASE; RESULTS OF THE GERMAN CML STUDY IV
| 0479 |
| Saussele, Susanne,
Lauseker, M.,
Gratwohl, A.,
Beelen, D.W.,
Bunjes, D.,
Schwerdtfeger, R.,
Kolb, H.J.,
Ho, A.D.,
Falge, C.,
Holler, E.,
Schlimok, G.,
Zander, A.,
Arnold, R.,
Kanz, L.,
Dengler, R.,
Haferlach, C.,
Schlegelberger, B.,
Pfirrmann, M.,
Müller, M.C.,
Schnittger, S.,
Leitner, A.,
Pletsch, N.,
Hochhaus, A.,
Hasford, J.,
Hehlmann, R.,
For, The Germa
(Mannheim, Germany) |
| |
| 09:00-09:15 |
|
PHASE II MULTICENTRIC EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM) IN ELDERLY PATIENTS WITH PH CHRONIC MYELOID LEUKEMIA (CML) WHO ACHIEVED A STABLE COMPLETE CYTOGENETIC RESPONSE (CCGR) WITH STANDARD IM THERAPY
| 0480 |
| Russo, Domenico,
Rosti, Gianantonio,
Martinelli, Giovanni,
Malagola, Michele,
Mirto, Salvatore,
Turri, Diamante,
Vitolo, Umberto,
Pregno, Patrizia,
Gobbi, Marco,
Pierri, Ivana,
Di Raimondo, Francesco,
Stagno, Fabio,
Foà, Robin,
Alimena, Giuliana,
Breccia, Marco,
Saglio, Giuseppe,
Rege Cambrin, Giovanna,
De Fabritiis, Paolo,
Abruzzese, Elisabetta,
Fanin, Renato,
Tiribelli, Mario,
Galieni, Piero,
Bigazzi, Catia,
Liso, Vincenzo,
Specchia, Giorgina,
Rambaldi, Alessandro,
Intermesoli, Tamara,
Lauria, Francesco,
Bocchia, Monica,
Quarta, Giovanni,
Girasoli, Mariella,
Angelucci, Emanuele,
Usala, Emilio,
Bosi, Alberto,
Santini, Valeria,
Colombi, Chiara,
Amabile, Marilina,
Fogli, Miriam,
De Vivo, Antonio,
Baccarani, Michele
(Brescia, Italy) |
| |
|